Published in:
Open Access
01-12-2022 | Central Nervous System Trauma | Research
Limits on using the clock drawing test as a measure to evaluate patients with neurological disorders
Authors:
Raheleh Heyrani, Atiye Sarabi-Jamab, Jordan Grafman, Nesa Asadi, Sarvenaz Soltani, Fatemeh Sadat Mirfazeli, Mostafa Almasi-Dooghaei, Seyed Vahid Shariat, Amin Jahanbakhshi, Tara Khoeini, Mohammad Taghi Joghataei
Published in:
BMC Neurology
|
Issue 1/2022
Login to get access
Abstract
Background
The Clock Drawing Test (CDT) is used as a quick-to-conduct test for the diagnosis of dementia and a screening tool for cognitive impairments in neurological disorders. However, the association between the pattern of CDT impairments and the location of brain lesions has been controversial. We examined whether there is an association between the CDT scores and the location of brain lesions using the two available scoring systems.
Method
One hundred five patients with brain lesions identified by CT scanning were recruited for this study. The Montreal Cognitive Assessment (MoCA) battery including the CDT were administered to all partcipants. To score the CDT, we used a qualitative scoring system devised by Rouleau et al. (1992). For the quantitative scoring system, we adapted the algorithm method used by Mendes-Santos et al. (2015) based on an earlier study by Sunderland et al. (1989). For analyses, a machine learning algorithm was used.
Results
Remarkably, 30% of the patients were not detected by the CDT. Quantitative and qualitative errors were categorized into different clusters. The classification algorithm did not differentiate the patients with traumatic brain injury ‘TBI’ from non-TBI, or the laterality of the lesion. In addition, the classification accuracy for identifying patients with specific lobe lesions was low, except for the parietal lobe with an accuracy of 63%.
Conclusion
The CDT is not an accurate tool for detecting focal brain lesions. While the CDT still is beneficial for use with patients suspected of having a neurodegenerative disorder, it should be cautiously used with patients with focal neurological disorders.